Keywords: biogen, halts, antova, trials, citing, serious, adverse
Biogen halts Antova trials, citing serious adverse events
Article | 26 October 1999
Biogen has halted several Phase II trials of Antova, its anti-CD40ligand monoclonal antibody, following the observation of thromboembolic events ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
